About
Resources
Blog
CDC Data
Infographics
Social Media Graphics
Papers
Podcasts
Videos
Webinars
Disease State
AFib
Heart Failure
High Cholesterol
Hypertension
Hypertrophic Cardiomyopathy
Obesity
Peripheral Artery Disease
Advocacy
ICER
MINI Act
No Big Deal
PCSK9 Rejections
Take Action
CLA
Contact
Subscribe
Contact PACH
Membership
Upcoming Events

Partnership to Advance Cardiovascular Health

About
Resources
Blog
CDC Data
Infographics
Social Media Graphics
Papers
Podcasts
Videos
Webinars
Disease State
AFib
Heart Failure
High Cholesterol
Hypertension
Hypertrophic Cardiomyopathy
Obesity
Peripheral Artery Disease
Advocacy
ICER
MINI Act
No Big Deal
PCSK9 Rejections
Take Action
CLA
Contact
Subscribe
Contact PACH
Membership
Upcoming Events
Statement on Centers for Medicare and Medicaid Services Proposed Rule on Obesity Coverage

Statement on Centers for Medicare and Medicaid Services Proposed Rule on Obesity Coverage

Genetically Targeted Technologies and the MINI Act

Genetically Targeted Technologies and the MINI Act

PACH One-Pager

Genetically Targeted Technologies: A Big Win for Heart Patients

Genetically Targeted Technologies: A Big Win for Heart Patients

PACH Infographic

A “MINI” Act Could Be Big for Patients

A “MINI” Act Could Be Big for Patients

Health Policy Today Blog

Overview and Outlook for RNA-Based Therapies

Overview and Outlook for RNA-Based Therapies

Avalere Study

Coverage for Obesity Treatment CMS Letter

Coverage for Obesity Treatment CMS Letter

IRA Drug Price Negotiation Impact on Cardiovascular Drugs

IRA Drug Price Negotiation Impact on Cardiovascular Drugs

Avalere Study

Press Release: CMS Semaglutide Coverage Expansion Could Save Millions of Lives

Press Release: CMS Semaglutide Coverage Expansion Could Save Millions of Lives

A group of health care and advocacy organizations is urging the Centers for Medicare & Medicaid Services (CMS) to expand coverage and access to semaglutide for the treatment of obesity. Doing so, the group says, could mitigate the detrimental outcomes and comorbidities that often develop as a result of obesity, a disease that places significant burdens on individuals and the health care system.

Post-Approval Indications and Clinical Trials for Cardiovascular Drugs: Some Implications of the US Inflation Reduction Act

Post-Approval Indications and Clinical Trials for Cardiovascular Drugs: Some Implications of the US Inflation Reduction Act

Article Published on the Journal of Medical Economics

The Dangers of Step Therapy for Heart Patients

The Dangers of Step Therapy for Heart Patients

Obesity

Obesity

Pressure’s Mounting: The Urgent Need for Innovation in Hypertension Care

Pressure’s Mounting: The Urgent Need for Innovation in Hypertension Care

For Some, Step Therapy Is a Matter of Death or Life

For Some, Step Therapy Is a Matter of Death or Life

POLL: HEALTH PLAN DELAYS ARE “UNREASONABLE,” DANGEROUS FOR HEART PATIENTS

POLL: HEALTH PLAN DELAYS ARE “UNREASONABLE,” DANGEROUS FOR HEART PATIENTS

It’s Time for Congress to Finally Treat Obesity Like the Epidemic It Is

It’s Time for Congress to Finally Treat Obesity Like the Epidemic It Is

State Leaders Tackle Obesity

State Leaders Tackle Obesity

Why Employers Should Invest in Obesity Treatment

Why Employers Should Invest in Obesity Treatment

Medicare Part D Extends Coverage of Obesity Treatments for New Indication

Medicare Part D Extends Coverage of Obesity Treatments for New Indication

A MINI Act Could Be Big for Heart Patients

A MINI Act Could Be Big for Heart Patients

A “MINI” Act Could Be Big for Patients

A “MINI” Act Could Be Big for Patients

Press Release: CMS Semaglutide Coverage Expansion Could Save Millions of Lives

Press Release: CMS Semaglutide Coverage Expansion Could Save Millions of Lives

A group of health care and advocacy organizations is urging the Centers for Medicare & Medicaid Services (CMS) to expand coverage and access to semaglutide for the treatment of obesity. Doing so, the group says, could mitigate the detrimental outcomes and comorbidities that often develop as a result of obesity, a disease that places significant burdens on individuals and the health care system.

IRA Drug Price Negotiation Impact on Cardiovascular Drugs

IRA Drug Price Negotiation Impact on Cardiovascular Drugs

Avalere Study

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
Previous Next
Statement on Centers for Medicare and Medicaid Services Proposed Rule on Obesity Coverage
Giving Hypertension Patients New Treatment Options
Genetically Targeted Technologies and the MINI Act
[Webinar] Genetically Targeted Technologies and the MINI Act
A MINI Act Could Be Big for Heart Patients
Genetically Targeted Technologies: A Big Win for Heart Patients
A “MINI” Act Could Be Big for Patients
Overview and Outlook for RNA-Based Therapies
Coverage for Obesity Treatment CMS Letter
IRA Drug Price Negotiation Impact on Cardiovascular Drugs
Press Release: CMS Semaglutide Coverage Expansion Could Save Millions of Lives
Post-Approval Indications and Clinical Trials for Cardiovascular Drugs: Some Implications of the US Inflation Reduction Act
The Dangers of Step Therapy for Heart Patients
Fail First Is Failing Heart Disease Patients
Barriers to Patient Access: Step Therapy
Obesity
Pressure’s Mounting: The Urgent Need for Innovation in Hypertension Care
Medicare and Obesity Treatment
2023 Cardiovascular Health Policy Summit
For Some, Step Therapy Is a Matter of Death or Life
POLL: HEALTH PLAN DELAYS ARE “UNREASONABLE,” DANGEROUS FOR HEART PATIENTS
It’s Time for Congress to Finally Treat Obesity Like the Epidemic It Is
State Leaders Tackle Obesity
Why Employers Should Invest in Obesity Treatment
Medicare Part D Extends Coverage of Obesity Treatments for New Indication
A MINI Act Could Be Big for Heart Patients
A “MINI” Act Could Be Big for Patients
Press Release: CMS Semaglutide Coverage Expansion Could Save Millions of Lives
IRA Drug Price Negotiation Impact on Cardiovascular Drugs
Back to Top

Partnership to Advance Cardiovascular Health